Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) received a drug registration certificate for its alendronate sodium oral solution issued under the authority of China's National Medical Products Administration, a Friday Hong Kong bourse filing said.
The drug is suitable for the treatment of osteoporosis in postmenopausal women to
prevent hip and spinal fractures and in men to increase bone mass.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.